Understanding when bowel changes represent a normal medication effect versus a potentially serious complication is essential for patient safety
In a large 56-week clinical trial that evaluated liraglutide in individuals who were overweight or had obesity, as well as had diabetes or prediabetes, participants reported statistically significant weight loss compared with those who took the placebo at the end of the study
marketed for diabetes as Mounjaro and for weight management under trade names such as Zepbound) Tirzepatide combines GLP-1 and GIP receptor agonism and has shown the largest average weight losses of any medication to date
What makes a peptide so hard to deliver through skin
doi: 10.4158/EP11009.OR
If you've already been comparison-shopping, you've probably run into names like Hers, Ro, Hims, ShedRx, altRx, Refills Health, SkinnyRx, MEDVi, GobyMeds, Mochi Health, or Noom Weight